Publications by authors named "Russel Pike"

Claim this Profile
T
Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors.
Latha G Nair, Stephane Bogen, Sumei Ruan, Weidong Pan, Russel Pike

Bioorg Med Chem Lett· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection.
Srikanth Venkatraman, Stéphane L Bogen, Ashok Arasappan, Frank Bennett, Kevin Chen, Russel Pike

J Med Chem· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication.
Stéphane L Bogen, Ashok Arasappan, Frank Bennett, Kevin Chen, Edwin Jao, Russel E Pike

J Med Chem· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5].
Frank Bennett, Anil K Saksena, Raymond G Lovey, Yi-Tsung Liu, Naginbhai M Patel, Russel Pike

Bioorg Med Chem Lett· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis